NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Janssen (Belgium) · Bristol-Myers Squibb (Germany) · +53 more institutions
Abstract
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder…
Citation impact
- FWCI
- 63.26
- Percentile
- 100%
- References
- 58
Authors
38- TWThomas W. FlaigCorresponding
Janssen (Belgium), Bristol-Myers Squibb (Germany), AVEO Oncology (United States), Astellas Pharma (China), Southwestern Medical Center, GlaxoSmithKline (India), Exact Sciences (United States), Lantheus Medical Imaging (United States), University of Colorado Cancer Center, AstraZeneca (Poland), AstraZeneca (Finland), Gilead Sciences (Australia), Harold C. Simmons Comprehensive Cancer Center, Merck Serono S.p.A. (Italy), The University of Texas Southwestern Medical Center, University of Colorado Denver
- PEPhilippe E. Spiess
Janssen (Belgium), Bristol-Myers Squibb (Germany), Moffitt Cancer Center, AVEO Oncology (United States), Astellas Pharma (China), Southwestern Medical Center, GlaxoSmithKline (India), Exact Sciences (United States), Lantheus Medical Imaging (United States), AstraZeneca (Poland), AstraZeneca (Finland), Gilead Sciences (Australia), Harold C. Simmons Comprehensive Cancer Center, Merck Serono S.p.A. (Italy), The University of Texas Southwestern Medical Center
- MAMichael Abern
Janssen (Belgium), Bristol-Myers Squibb (Germany), Cancer Institute (WIA), AVEO Oncology (United States), Astellas Pharma (China), Southwestern Medical Center, GlaxoSmithKline (India), Exact Sciences (United States), Lantheus Medical Imaging (United States), AstraZeneca (Poland), AstraZeneca (Finland), Gilead Sciences (Australia), Duke Cancer Institute, Harold C. Simmons Comprehensive Cancer Center, Merck Serono S.p.A. (Italy), The University of Texas Southwestern Medical Center
- NANeeraj Agarwal
Janssen (Belgium), Bristol-Myers Squibb (Germany), University of Utah, Huntsman Cancer Institute, AVEO Oncology (United States), Astellas Pharma (China), GlaxoSmithKline (India), Exact Sciences (United States), Lantheus Medical Imaging (United States), AstraZeneca (Poland), AstraZeneca (Finland), Gilead Sciences (Australia), Merck Serono S.p.A. (Italy)
- RBRick Bangs
Janssen (Belgium), Bristol-Myers Squibb (Germany), AVEO Oncology (United States), Advocate Health Care, Astellas Pharma (China), Southwestern Medical Center, GlaxoSmithKline (India), Exact Sciences (United States), Lantheus Medical Imaging (United States), AstraZeneca (Poland), AstraZeneca (Finland), Gilead Sciences (Australia), Harold C. Simmons Comprehensive Cancer Center, Merck Serono S.p.A. (Italy), The University of Texas Southwestern Medical Center
Topics & keywords
- Medicine
- Bladder cancer
- Prostate cancer
- Oncology
- Cancer
- Economic shortage
- Urology
- Internal medicine
- Good health and well-being